Bureaucrats, editor, reviewer, Administrators
2,392
edits
ALLHAT: Difference between revisions
Jump to navigation
Jump to search
no edit summary
(misc fixes including N/n issue) |
No edit summary |
||
| Line 63: | Line 63: | ||
==Measured outcomes and results== | ==Measured outcomes and results== | ||
===Base-line Characteristics=== | |||
* Mean age: 67 years | |||
* Male: 53% | |||
* Black: 35%; Hispanic: 19% | |||
* Diabetes: 36% | |||
===Primary outcomes=== | ===Primary outcomes=== | ||
* Combined fatal coronary heart disease (CHD) or non-fatal MI | * Combined fatal coronary heart disease (CHD) or non-fatal MI | ||
** Amlodipine vs Chlorthalidone: NS (RR 0.98, 95% CI 0.90-1.07) | |||
** Lisinopril vs Chlorthalidone: NS (RR 0.99, 95% CI 0.91-1.08) | |||
===Secondary outcomes=== | ===Secondary outcomes=== | ||
* All-cause mortality | * All-cause mortality | ||
** Amlodipine vs Chlorthalidone | |||
** Lisinopril vs Chlorthalidone | |||
* Fatal and nonfatal stroke | * Fatal and nonfatal stroke | ||
** Lisinopril group had 15% higher risk for stroke (p=0.02) | |||
* Combined CHD (primary outcome, coronary revascularization, or angina with hospitalization) | * Combined CHD (primary outcome, coronary revascularization, or angina with hospitalization) | ||
* Combined CVD (combined CHD, stroke, treated angina without hospitalization, HF [fatal, hospitalized, or treated nonhospitalized], and peripheral arterial disease) | * Combined CVD (combined CHD, stroke, treated angina without hospitalization, HF [fatal, hospitalized, or treated nonhospitalized], and peripheral arterial disease) | ||
** Amlodipine group had 38% higher risk of HF (p<0.001), 6-year absolute risk difference of 2.5% and 35% higher risk of hospitalized/fatal HF (p<0.001) | |||
===Subgroup analysis=== | ===Subgroup analysis=== | ||
* | * | ||